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CObjectives: Our aim was to compare the cost-effectiveness of two na-
tional cervical cancer screening programs aiming to involve those who
do not regularly participate in the screening program in Hungary with
no screening, using a public health-care payer’s perspective and a 20-
year time horizon. Methods: We built a Markov model based on dis-
ase progression. The health-care costs of screening and treatment
ere received from real-word data. Other input data were obtained
rom the literature. The cost-effectiveness of the current screening pro-
ram (a screening test that combines cytology and colposcopy in gyne-
ological outpatient services) and of a planned new screening program
only cytology, and Pap smear is taken locally by public health nurses),
oth supported with a more active communication campaign, were
ompared with no screening. Results: The incremental cost-effective-
ess ratio of the intensified current screening practice was $33,100 per
uality-adjusted life-year compared with no screening, whereas thencremental cost-effectiveness ratio of the renewed program was O
s
d
w
h
o rep
Polic
117
al So
oi:10.1016/j.jval.2011.10.00318,990 per quality-adjusted life-year compared with no screening. The
ost influential parameters in the deterministic analysis were the
uality-of-life weights of undetected stage I or IIA cancer. In the prob-
bilistic sensitivity analysis, 99.9% of the simulations were below the
ncremental cost-effectiveness ratio of $30,000 per quality-adjusted
ife-year in the case of the renewed strategy. Conclusions: Providing
ervices closer to the population is a rational economic option for the
eform of the Hungarian cervical cancer screening program. The other
olicy aspects of this development, human resource need, stakehold-
rs’ interests, organizational aspects, and attitude of the target popu-
ation need to be carefully considered.
eywords: cost-effectiveness, economic models, Hungary, mass
creening, uterine cervical neoplasms.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
The mortality of cervical cancer is comparatively high in Hungary:
the crude death rate was 7.9 per 100,000 women in 2008 [1]. An
organized cervical cancer screening program was launched for
women aged 25 to 65 years in 2003 as part of the National Public
Health Program. Women were invited to undergo cervical screen-
ing every 3 years. The method of screening followed the long-
standing Hungarian professional tradition of opportunistic
screening; it included Papanicolaou test and colposcopic exami-
nation performed by gynecologists in outpatient services located
in cities. Although data about the participation rates are some-
what contradictory, one can conclude that 50% to 60% of women
aged 25 to 65 years regularly visit a gynecologist and undergo cer-
vical screening without any organized program. Over 7 years, the
organized screening program did not significantly increase the
proportion of the regularly screened population [2,3].
The National Public Health and Medical Officers’ Service (NPH-
MOS), which is responsible for the organization of the screening
program, realized the inefficiency of the system and performed
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098-3015/$36.00 – see front matter Copyright © 2012, Internation
ublished by Elsevier Inc.pilot projects to develop a new strategy. In one of the pilot projects,
public health nurses were trained to obtain a cervical smear and
they provided the service locally, even in small villages. The pro-
gram targeted marginalized populations and did not include col-
poscopic examination. The promising results regarding the qual-
ity of the service and participation of the population made this
method a potential option for reform of the national program. Our
study aimed to estimate the cost-effectiveness of different cervi-
cal screening programs in Hungary to support health policy deci-
sion making.
Methods
We developed a cohort simulation Markov model in Microsoft Ex-
cel. Although several models of the cost-effectiveness of cervical
screening programs have been published [4–6], none was directly
uitable for our research question on the cost-effectiveness of the
ifferent methods to increase participation of those Hungarian
omen in cervical screening program who would not use this
ealth service otherwise (i.e., not using opportunistic screening). It
ort.
y and Health Economics, Institute of Economics, Faculty of Social
Budapest, Hungary.
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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40 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 3 9 – 4 5was either not possible to rebuild previously published models or
all relevant aspects of the Hungarian screening strategies (e.g., use
of colposcopy) were not possible to be modeled.
Model structure
We adopted, modified, and rebuilt a previously published model
[7]. Like other published models, this model was not suitable for all
aspects of the Hungarian screening program, but we could use the
core part of the model about disease progression. The original
model was based on disease progression and also contained
health states of low-risk human papilloma virus (HPV) infections,
which we did not include in our model. The simplified model we
actually used is presented in Figure 1. The boxes of the figure
represent health states, and the arrows represent transition
routes between health states. Cervical intraepithelial neoplasia
(CIN) is precancerous alteration of the cervix epithelium. These
changes might be benign or infectious in nature, but the more
advanced alterations are at high risk of transforming to cancer.
The “cancers detected” states are modeled in two separate states,
“newly detected” (3 months after detection) and “treated,” to ac-
count for the differences in quality of life (QoL) and immediate and
long-term costs. The model estimates the lifespan of women (aged
25–64 years) on the basis of participation in regular screening. The
model is split into 5-year age cohorts. On the basis of incidence
rates from the literature [8], we calculated the transition probabil-
ities for the cycle length of 1 month by using constant incidence
rate assumption. For example, at age 35 to 39 years, the incidence
rate from CIN 2, CIN 3, and HPV state to cancer I and IIA nonde-
tected state was estimated at 0.022 per person-year. Assuming
constant incidence rate, the estimated 1-month risk, the transi-
tional probability can be calculated as follows:
risk1 month 1 e
0.022(1⁄12) 0.001832
The current prevalence of different stages was estimated by
sing published data [5,9,10]. We attached QoL weights to each
ealth state (Table 1). The age-specific QoL weights in the gen-
ral population were taken from the Hungarian National Health
Fig. 1 – Health states of the disease progression model. CC, c
papilloma virus.urvey 2000 [11]. The QoL weights of undiagnosed and treatedancer are expert estimations, whereas the QoL weights of
ewly diagnosed cancers in different stages were taken from
he literature [8].
To confirm the calibration of our model, we compared the pre-
icted number of newly diagnosed cervical cancer cases in case
his population was not involved in the screening program, as is
he case currently, with the number of new cervical cancer cases
eported in the National Cancer Registry in 2007.
Different disease stages may be diagnosed at certain probabil-
ties depending on the characteristics of the screening test
Table 2) [4,7,12–14]. P1 to P5 stands for Papanicolaou classification
f the cervical smear cytology from “normal” to “invasive cancer”
12]. According to current Hungarian practice, if a person has a P3
ytology result, she receives a combination local anti-inflamma-
ory treatment and the cytology is repeated within 2 weeks. If the
ubsequent result is P3 or worse again, then conization is offered
ust like for those who had a P4 or P5 result initially. If the subse-
uent result after an initial P3 cytology is P2, then the cytology is
epeated again in 6 months. If this result is P1 or P2, then the
atient returns to the regular screening regimen. If the result is
orse than P2, conization is offered.
The effect of early detection and treatment was modeled in
uch a way that if someone undergoes a conization, then she is
r; CIN, cervical intraepithelial neoplasia; HPV, human
Table 1 – Quality-of-life weights* corresponding to
different cancer stages.
Nondetected Newly detected Treated
CC I-IIA 1.0 (0.1000) 0.68 (0.0680) 0.95 (0.0950)
CC IIB-III 0.95 (0.0950) 0.56 (0.0560) 0.75 (0.0750)
CC IV 0.9 (0.0900) 0.48 (0.0480) 0.60 (0.0600)
The numbers in parentheses are the standard errors applied for the
distributions in the probabilistic sensitivity analysis.
CC, cancer.
* The age-specific quality-of-life weights are multiplied with theseanceweights.
41V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 3 9 – 4 5moved back to the initial health stage of no CIN and no HPV
infection.
The effect of cancer treatment is reflected in the model by stop-
ping the progression of cancer if it is detected. Nevertheless, the
cancer treatment was not assumed to be 100% effective, because
the mortality rates in the detected cancer states were much larger
than the corresponding age-specific mortality rates.
The discount rates of cost and quality-of-life years (quality-
adjusted life-year [QALY]) are user input in the model. In the de-
fault model, we used 5% for both, which is in line with the current
Hungarian guideline of health economic evaluations [15]. Our
analysis was conducted from the public health-care payer’s per-
spective.
Cost data
Resource utilization data of the screening process was estimated
per protocol: resource units were multiplied by the tariffs of the
National Health Insurance Fund (NHIF) for the services. The costs
of the Pap smear (NHIF procedure code: 14720), the cytological
examination (NHIF procedure code: 42700), and gynecological
screening examination (NHIF procedure code 16631 plus 42600)
were $0.68, $11.82, and $11.27, respectively. The price of local anti-
inflammatory treatment was $5.80. The cost of the conization was
$1390.6. The cost of conization was calculated by the cost of the
diagnosis-related group “operation of uterus and adnexum of
uterus due to in situ carcinoma and nonmalignant disease” coded
as 643B. Costs of care in different stages of cervical cancer were
calculated from real-world data. Patients with different stages of
newly diagnosed cervical cancer in 2006 at the Clinics of Obstetrics
and Gynecology at the University of Debrecen and at the Depart-
ment of Gynecology and Obstetrics at the Saint Stephen Hospital
were identified. The patient’s social security number was matched
with individual resource utilization and payment records in the
NHIF database. The NHIF was one of the participants in the re-
search consortium led by the Institute of Healthcare Quality Im-
provement and Hospital Engineering, commissioned by the Min-
istry of Health. The total health-care cost by cancer stage in
respect to time after the diagnosis was calculated from aggregated
payment records (Table 3). It included acute and chronic inpatient
care, outpatient care, imaging (computed tomography and mag-
netic resonance), home care, and drug costs.
The cost of traveling was included among the costs, because it
is reimbursed to the screening participants by the NHIF. The cost
of traveling can be set in the model; the default value ($7.40) was
based on the average distance from outpatient services in the dis-
advantaged areas. If the screening is done locally, then the num-
ber of examinations performed on each occasion can also be set.
The default value is set to 20. In this case, the traveling cost per
examination is only $0.37 because it is the service provider who
needs to travel.
The organizational cost of the screening program can also be
set. Based on the information we received from the NPHMOS, the
default value for one round of the screening program was set to
$666,000 per 1.7 million people (the currently unscreened popula-
Table 2 – The default setting of the distribution of the scree
screening method.
Test result Only cytology
Normal CIN 1 CIN 2 and 3 CC I C
P1-P2 0.95 0.517 0.472 0.286
P3 0.04 0.448 0.493 0.286
P4-P5 0.01 0.035 0.035 0.428
CC, cancer; CIN, cervical intraepithelial neoplasia.tion from age 25 to 64 years). In addition, the cost of $1.48 perperson was calculated for direct communication. The cost of the
training of public health nurses was estimated as $74,000 per year
on the basis of data of the NPHMOS.
The model calculates cost in Hungarian forint (HUF). In this
article, we used the purchasing power parity exchange rate of 135
HUF per dollar rate, which eliminates differences in price levels
between countries [16].
We did not consider indirect costs in the analysis.
Strategies modeled
Many strategies can be modeled according to the different combi-
nations of the input parameters. One can set the time interval of
the screening examination (2 or 3 years), the method of screening
(locally, cytology only, or cytology combined with colposcopy in
outpatient services), and the target participation rate by age group.
The model compares the total QALYs and the total costs ex-
pected in 20 years in the target population if the specified screen-
ing program is performed or if there is no screening. It calculates
costs and QALYs by age cohorts, the weighted average of these,
and an extrapolated value for the population involved. Incremen-
tal cost-effectiveness ratios (ICERs) were calculated by dividing the
cost difference with the difference in QALYs.
In this analysis we compared two scenarios to no organized
screening. In Scenario 1, the current practice of screening by cy-
tology and colposcopy in outpatient services by gynecologists con-
tinues, and it is supported more actively (e.g., increased presence
on mass media, letters, information leaflets, involvement of local
opinion leaders, and general practitioners) than the current com-
munication campaign to reach and motivate the target popula-
tion. In Scenario 2, the Pap smear is performed by trained public
health nurses locally in the offices of the general practitioners. In
this case, colposcopic examination was not included. Based on
policy discussions and a pilot study, this is the most likely strategy
to improve the Hungarian national cervical screening program.
The same communication support was assumed in this scenario.
We assumed that because of the communication efforts 50% par-
ticipation rate would be achieved in all age groups by both scenar-
test results according to the disease stages and the
Cytology and colposcopy
-IV Normal CIN 1 CIN 2 and 3 CC I CC II-IV
0.31 0.1 0.04 0.01 0
0.621 0.45 0.48 0.04 0
0.069 0.45 0.48 0.95 1
Table 3 – Direct medical cost ($) per month of cervical
cancer by stages and time after the diagnosis.
Stage Time after the diagnosis
Months 0-3 Months
4-12
Months
13-24
From
month
25
CC I-IIA 1076 (268.98) 201 (50.27) 147 (36.64) 92 (22.99)
CC IIB-III 1076 (268.98) 329 (82.32) 315 (78.63) 263 (65.63)
CC IV 1076 (268.98) 327 (81.75) 416 (104) 305 (76.25)
The numbers in parentheses are the standard errors applied for the
distributions in the probabilistic sensitivity analysis.ning
C II
0
0
1CC, cancer.
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would be involved.
We performed deterministic and probabilistic sensitivity anal-
yses. We tested how robust the results were to10% change of the
input parameters. In the probabilistic sensitivity analysis, we de-
fined distributions for the key input parameters and conducted
5000 Monte Carlo simulations with sampling from these distribu-
tions. Gamma distributions were applied for incidence rates of
transitions, participation rates, cancer stage–specific mortality,
stage-specific health-care costs, and organizational costs of
screening. Beta distributions were applied for participation rates
in screening and QoL weights of cancer states. Dirichlet distribu-
tions were applied for the initial prevalence figures of the different
health states and for the proportions of screening test results ac-
cording to the disease state. We plotted the results on an accept-
ability curve.
Results
Our model was undercalibrated in the young age groups, and it
was well calibrated above age 44 years; that is, the number of the
estimated new cases with no further development of the screen-
ing program was consistent with the actual incident cases regis-
tered in the National Cancer Registry (Table 4). When interpreting
this finding, one needs to consider that some cervical cancer cases
occur in the screened population as well; thus, not all the reported
cases are expected to occur among women who do not regularly
undergo screening. Table 5 shows the cost and the QALYs corre-
ponding to the two scenarios and no screening. Both screening
trategies were cost-effective if we consider that three times the
DP/inhabitant ratio ($58,700) is the informal threshold of cost-
ffectiveness. The health gain was larger in Scenario 1 than in
cenario 2 by 1025 QALYs for the population. However, the extra
ost of this was substantial: $86.8 million. The ICER of Scenario 1
Table 4 – The estimated number of new cervical cancer cas
Cancer Registry.
Age group (y) Age cohort weight in
the population (%)
25–34 27
35–44 23
45–54 26
55–64 24
25–64 100
The numbers in parentheses are the range of the values obtained in
Table 5 – Cost-effectiveness of the different screening scen
Scenario 1
Cost ($) per person 297 (237–352) 1
QALYper person 11.1740 (10.9399–11.3581) 11.17
Cost ($) per person
per population
230 (199–256)
157,862,382
QALY per person
per population
0.00695 (0.00239–0.01773)
4769
0.005
ICER ($ per QALY) 33,100
The numbers in parentheses are the range of the values obtained in
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted lif
* When it was compared with Scenario 1.
† When it was compared with Scenario 2.ompared with that of Scenario 2 was $84,564 per QALY, far be-
ond the informal cost-effectiveness threshold.
Table 6 shows the dependence of cost-effectiveness on the age
f the participants. The data show that even in the case of the
ore cost-effective Scenario 2, the ICER is lower than the informal
ost-effective threshold only above 30 years of age.
Decreased discount rate and later starting age of the screening
rogram considerably decreases the ICER. On the other hand, in-
reasing the frequency of the screening greatly increases the ICER,
hat is, makes the screening much less cost-effective (Table 7).
igure 2 shows how the cost-effectiveness of the two strategies
epends on the participation rate. It can be seen that the curves
each a kind of asymptote; the ICERs do not change much above
he participation rate of 50%.
The results were robust to the uncertainty of 10% change in the
ost influential input parameter, QoL weights of undetected stage
or IIA cancer, which did not change the ICER of Scenario 2 more
han $3500 per QALY (Fig. 3). The variability of the results in the
robabilistic sensitivity analysis is presented in Table 5 together
ith the point estimates. All simulated results were situated in the
ortheast quadrant of the cost-effectiveness planes (figures not
hown). The cost-effectiveness acceptability curve of Scenario 2
hows that 99.9% of the simulations provided an ICER below
30,000 per QALY, whereas only 72% of the simulations produced
n ICER below this level in case of Scenario 1 (Fig. 4).
Discussion
The organized cervical cancer screening program that started in
2003 has not fulfilled the expectations; it has not significantly in-
creased the proportion of the regularly screened population in
Hungary. The main reasons for this failure are service organiza-
tion (gynecological outpatient services in cities) and ineffective
communication [3]. Results from health surveys show that the
nd the actual number of cases registered in the National
Estimated number of
cases in the first year
Registered number of
new cases in 2007
15 (12–18) 108
69 (56–84) 220
218 (184–265) 278
241 (199–291) 218
543 824
robabilistic sensitivity analysis.
.
nario 2 No screening
23–222) 67 (38–95),* (38–123)†
0.9614–11.3658) 11.1670 (10.9375–11.3403)*
(10.9570–11.3510)†
(86–136)
,096,011
Reference
.00443–0.01476)
3744
Reference
18,990 Reference
robabilistic sensitivity analysis.
r.es aarios
Sce
71 (1
25 (1
104
71
46 (0
the p
e-yea
43V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 3 9 – 4 5majority of women who do not use cervical screening services are
less educated women in smaller communities. Opportunistic and
organized screening occurs at higher rates in big cities. The
NPHMOS, the organization responsible for the management of the
national screening programs, is currently working on the reform
of the cervical screening program. It has launched pilot projects to
test how bringing the service closer to the target population works.
The initial results were promising with the involvement of spe-
cially trained public health nurses performing Pap smears locally
in the general practitioners’ offices. Furthermore, NPHMOS is to
launch large-scale communication programs about cancer screen-
ing, including the cervical cancer screening program, and it also
supports local, more personalized communications. Our study
was part of the process of collecting evidence supporting the re-
form of cancer screening programs. The two potential scenarios
studied were the intensified current program (i.e., the current
screening program with a more efficient communication) and re-
newing the methodology of the screening (performing Pap smears
locally by public health nurses and using only cytology without
colposcopy) together with a more efficient communication.
Our results showed that the newly planned strategy is more cost-
effective than the intensified present program compared with no
screening. Furthermore, the intensified current strategy is not cost-
effective compared with the new strategy; thus, the planned devel-
opment is reasonable from the health economic point of view.
Another important result was that neither screening strategy was
cost-effective under the age of 30 years; there is very limited room for
health gain in this age group because of the low incidence of the
disease. However, when interpreting this finding, one needs to take
into account that our model was undercalibrated under the age of
45 years. If the reported high incidence in young women is valid,
and all these cases occur among unscreened women, then the
potential health gain by screening is higher in these age groups;
thus, the screening is more cost-effective than as we estimated.
Table 6 – The cost-effectiveness of the screening
strategies compared with no screening in the different
age groups.
Age group (y) ICER ($ per QALY)
Scenario 1 Scenario 2
25–29 116,969 64,799
30–34 73,687 37,929
35–39 38,898 22,073
40–44 31,187 17,952
45–49 26,077 15,071
50–54 24,480 14,266
55–59 24,764 14,544
60–64 25,628 15,175
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted
life-year.
Table 7 – The effect of major input parameters on the cost-
screening.
Scenario 1
QALY cost ($) ICER
Default (in Table 5) 0.00695 230
Discount rate 3% 0.00911 267
Frequency of screening 2 y 0.008 361
Starting age 35 y 0.00791 217ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-yeaOur results regarding the cost-effectiveness of the new strat-
egy are conservative because of another reason as well. We as-
sumed that the same participation rate could be achieved with the
same investment in communication. Nevertheless, on the basis of
the results of some pilot projects, we can assume that a higher
participation rate could be achieved with the same per capita in-
vestment by the involvement of local opinion leaders and local
communication campaigns. If the participation rate were in-
creased to 70% from the default 50% in Scenario 2, then the ICER
comparing this strategy to no screening would decrease from
$18,990 per QALY to $18,169 per QALY.
Like any health economic model, ours is also prone to uncer-
tainties of the model structure and its parameters. We used the
best available evidence, tested the calibration of the model, and
used sensitivity analysis to test the robustness of our conclusions.
The number of new cervical cancer cases estimated by the model
was in accord with the actual number of cases reported in the
National Cancer Registry above age 44 years. The results were sen-
sitive for the length of the screening interval. Decreasing the in-
terval to 2 years would proportionally increase the cost more than
the health gain; the ICER would thus increase considerably. Like
the cost-effectiveness of many other preventive measures, the
cost-effectiveness of cervical cancer screening is also sensitive to
the discount rate applied. Because the current investment will
produce health benefits only in the long run, the high discount rate
devalues the benefit more than the cost.
Regarding the screening examination itself, we modeled the
current Hungarian practice. Although the current official Hungar-
ian guidelines recommend changing the cytology classification to
the Bethesda system, the majority of current practices still use the
Papanicolau classification; therefore, we used the latter in our
tiveness of the screening strategies compared with no
Scenario 2
er QALY) QALY cost ($) ICER ($ per QALY)
100 0.00546 104 18,990
280 0.00718 120 16,646
114 0.00678 167 24,629
432 0.00618 100 16,095
Fig. 2 – The relationship between the incremental cost-
effectiveness ratio and the participation rate by screening
strategy. ICER, incremental cost-effectiveness ratio; QALY,
quality-adjusted life-year.effec
($ p
33,
29,
45,
27,r.
44 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 3 9 – 4 5model. Moreover, HPV testing is part of the screening protocol in
many countries, but this is not the case in Hungary. Therefore, we
did not include HPV testing in the model.
A limitation of our study is that the cost estimation of cervical
cancer was based on data of only two health centers. Nevertheless,
they provided care for more than 10% of patients with newly di-
agnosed cancers; thus, the sampling size was reasonably large. We
selected a general hospital from the capital and a university clinic
from the country. Nonetheless, the sample cannot be considered a
representative sample. This, however, could not largely bias our
results, because gynecologists follow the national guideline in the
care of cervical cancer patients [17]. Furthermore, we tackled this
problem in the sensitivity analysis. Our cost estimates are still the
best available, because they are stage-specific ones. The optimal
solution—having a random sample of all new cervical cancer
cases—was not feasible in our study.
The cost-effectiveness of cervical screening was already as-
Fig. 3 – Sensitivity of the cost-effectiveness of Scenario 2 to ±
cancer; ICER, incremental cost-effectiveness ratio; QALY: qu
Fig. 4 – The cost-effectiveness acceptability curve of
Scenario 1 and Scenario 2 compared with no screening.
The straight line represents Scenario 1, the dotted line
Scenario 2, and the vertical line represents the informal
Hungarian cost-effectiveness threshold of $55,800 per
QALY. QALY, quality-adjusted life-year.sessed in Hungary in 2003 [18]. In that economic evaluation, au-
thors assumed that increased screening participation of women
aged 25 to 65 years could prevent 19.6% to 38.4% of mortality from
cervical cancer over 10 years in Hungary according to the different
scenarios analyzed. Treatment costs of cervical cancer were not
calculated according to cancer stages. The economic evaluation
was based on the assumption that increased cervical screening
participation did not change the national treatment cost of cervi-
cal cancer; therefore, incremental costs were attributable only to
the increased cost of screening. The incremental cost of screening
divided by the avoided death cases resulted in 16.6 to 33.8 million
HUF per life gained. On the basis of a British study, the authors
assumed that one avoided death case could result in 23 additional
life-years [19]; therefore, one life-year gain can be achieved at 0.7
to 1.5 million HUF incremental cost. As the methodology and the
assumptions of that cost-effectiveness analysis, especially the cal-
culation of life-years gained and the constant treatment cost, were
subject to criticism, the Ministry of Health initiated an economic
evaluation of intensified cervical screening in a disease state eco-
nomic model under the leadership of the Institute of Healthcare
Quality Improvement and Hospital Engineering. The project pre-
sented in this article included the development of an economic
model and a cost estimation study based on individual medical
and resource utilization records of patients in different cancer
states selected from two major medical centers.
Opportunistic cervical cancer screening has a long tradition in
Hungary. The organized cervical cancer screening program needs
to target women who otherwise would not utilize this service. Our
results showed that moving the service closer to the population is
a cost-effective strategy.
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